{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:50:22Z","timestamp":1791348622360,"version":"4.3.1"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1097\/inf.0000000000005430","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:01:36Z","timestamp":1791345696000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Long-acting Lipoglycopeptides for the Treatment of Gram-positive Infections in Children"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9411-8189","authenticated-orcid":false,"given":"Anna","family":"Gamell","sequence":"first","affiliation":[{"name":"Infectious Diseases and Systemic Inflammatory Response in Pediatrics, Pediatric Infectious Diseases Department, Institut de Recerca Sant Joan de D\u00e9u, Hospital Sant Joan de D\u00e9u, Barcelona, Spain"},{"name":"Department of Surgery and Medical-Surgical Specialties, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eneritz","family":"Velasco-Arnaiz","sequence":"additional","affiliation":[{"name":"Infectious Diseases and Systemic Inflammatory Response in Pediatrics, Pediatric Infectious Diseases Department, Institut de Recerca Sant Joan de D\u00e9u, Hospital Sant Joan de D\u00e9u, Barcelona, Spain"},{"name":"Department of Surgery and Medical-Surgical Specialties, Faculty of Medicine and Health Sciences, Universitat de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Aguilera-Alonso","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Diseases Unit, Department of Pediatrics, Hospital Gregorio Mara\u00f1\u00f3n, Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria Gregorio Mara\u00f1\u00f3n (IiSGM), Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Goretti","family":"L\u00f3pez-Ramos","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Hospital Sant Joan de D\u00e9u, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"R1-20261007","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3390\/pathogens13030189","article-title":"New frontier on antimicrobial therapy: long-acting lipoglycopeptides.","volume":"13","author":"Siciliano","year":"2024","journal-title":"Pathogens"},{"key":"R2-20261007","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/jac\/dku401","article-title":"Good practice recommendations for paediatric outpatient parenteral antibiotic therapy (p-OPAT) in the UK: a consensus statement.","volume":"70","author":"Patel","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"R3-20261007","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S1473-3099(17)30345-6","article-title":"Inpatient versus outpatient parenteral antibiotic therapy at home for acute infections in children: a systematic review.","volume":"18","author":"Bryant","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R4-20261007","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3390\/antibiotics14020121","article-title":"Bridging the gap: a systematic review with expert opinion on the use of dalbavancin for in-label and off-label indications in pediatric patients.","volume":"14","author":"Caselli","year":"2025","journal-title":"Antibiotics (Basel)"},{"key":"R5-20261007","doi-asserted-by":"crossref","first-page":"102431","DOI":"10.1016\/j.cpr.2024.102431","article-title":"Adjustment and homesickness in hospitalised children: a systematic review.","volume":"110","author":"Demetriou","year":"2024","journal-title":"Clin Psychol Rev"},{"key":"R6-20261007","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s40265-015-0505-8","article-title":"Lipoglycopeptide antibacterial agents in gram-positive infections: a comparative review.","volume":"75","author":"Van Bambeke","year":"2015","journal-title":"Drugs"},{"key":"R7-20261007","doi-asserted-by":"crossref","first-page":"e0261420","DOI":"10.1128\/aac.02614-20","article-title":"New perspectives on antimicrobial agents: long-acting lipoglycopeptides.","volume":"66","author":"Tran","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-20261007","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/INF.0000000000003798","article-title":"The safety and efficacy of dalbavancin and active comparator in pediatric patients with acute bacterial skin and skin structure infections.","volume":"42","author":"Giorgobiani","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"R11-20261007","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/INF.0000000000000646","article-title":"Pharmacokinetics, safety and tolerability of single dose dalbavancin in children 12-17 years of age.","volume":"34","author":"Bradley","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R12-20261007","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1097\/INF.0000000000001538","article-title":"Dalbavancin pharmacokinetics and safety in children 3 months to 11 years of age.","volume":"36","author":"Gonzalez","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R13-20261007","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/INF.0000000000003764","article-title":"Population pharmacokinetic and pharmacokinetic\/pharmacodynamic target attainment analyses for dalbavancin in pediatric patients.","volume":"42","author":"Carrothers","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"R14-20261007","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jgar.2017.06.003","article-title":"Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).","volume":"11","author":"Pfaller","year":"2017","journal-title":"J Glob Antimicrob Resist"},{"key":"R15-20261007","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s10096-016-2845-z","article-title":"Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE).","volume":"36","author":"Knafl","year":"2017","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Supplement_1","key":"R16-20261007","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/jpids\/piac041.012","article-title":"#13 Dalbavancin activity against bacterial isolates from pediatric patients: results from the international dalbavancin evaluation of activity (IDEA) program for the United States and Europe (2019-2021).","volume":"11","author":"Sader","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R18-20261007","first-page":"78","article-title":"Real-world use of dalbavancin for treatment of soft tissue and bone infection in children: safe, effective and hospital-time sparing.","volume":"11","author":"Caselli","year":"2024","journal-title":"Children (Basel)"},{"key":"R19-20261007","first-page":"88","article-title":"Case series: use of dalbavancin for invasive gram-positive infection in children.","volume":"31","author":"Chang","year":"2026","journal-title":"J Pediatr Pharmacol Ther"},{"key":"R20-20261007","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1093\/jac\/dkae212","article-title":"Off-label use of dalbavancin in children: a case series.","volume":"79","author":"Gamell","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"R21-20261007","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1097\/INF.0000000000004883","article-title":"Case series: off-label use of dalbavancin in pediatric gram-positive infections.","volume":"44","author":"Guill\u00e9n-Mart\u00ednez","year":"2025","journal-title":"Pediatr Infect Dis J"},{"key":"R22-20261007","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3390\/antibiotics15020162","article-title":"TDM-guided dalbavancin treatment for complex staphylococcus aureus osteoarticular infections in children.","volume":"15","author":"Garazzino","year":"2026","journal-title":"Antibiotics (Basel)"},{"key":"R23-20261007","doi-asserted-by":"crossref","first-page":"106960","DOI":"10.1016\/j.ijantimicag.2023.106960","article-title":"Expert opinion on dose regimen and therapeutic drug monitoring for long-term use of dalbavancin: expert review panel.","volume":"62","author":"Senneville","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"R24-20261007","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlac120","article-title":"Dalbavancin in clinical practice in Spain: a 2 year retrospective study.","volume":"4","author":"Morata","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"R25-20261007","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/FTD.0000000000001325","article-title":"Dalbavancin pharmacokinetics in an 18-month-old child undergoing extracorporeal membrane oxygenation.","volume":"47","author":"Cafaro","year":"2025","journal-title":"Ther Drug Monit"},{"issue":"Suppl 3","key":"R26-20261007","doi-asserted-by":"crossref","first-page":"S214","DOI":"10.1093\/cid\/cir920","article-title":"Oritavancin: mechanism of action.","volume":"54","author":"Zhanel","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R27-20261007","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12879-023-08725-8","article-title":"Oritavancin as sequential therapy for Gram-positive bloodstream infections.","volume":"24","author":"Texidor","year":"2024","journal-title":"BMC Infect Dis"},{"key":"R28-20261007","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3390\/antibiotics14020190","article-title":"Multidose dalbavancin population pharmacokinetic analysis for prolonged target attainment in patients requiring long-term treatment.","volume":"14","author":"Baiardi","year":"2025","journal-title":"Antibiotics (Basel)"},{"key":"R29-20261007","doi-asserted-by":"crossref","first-page":"e0183024","DOI":"10.1128\/aac.01830-24","article-title":"Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections.","volume":"69","author":"Cojutti","year":"2025","journal-title":"Antimicrob Agents Chemother"},{"key":"R30-20261007","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkag039","article-title":"Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500\u2009mg at days 1, 15 and 43 in bone and joint or cardiovascular infection.","volume":"81","author":"Lin","year":"2026","journal-title":"J Antimicrob Chemother"},{"key":"R31-20261007","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkag117","article-title":"Extrapolation of oritavancin PK\/PD targets to inform therapeutic drug monitoring: a systematic review.","volume":"81","author":"Baiardi","year":"2026","journal-title":"J Antimicrob Chemother"},{"key":"R32-20261007","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/pharmaceutics18050628","article-title":"Oritavancin multiple dosing for complex infections: a pharmacokinetic\/pharmacodynamic simulation study.","volume":"18","author":"Alarcia-Lacalle","year":"2026","journal-title":"Pharmaceutics"},{"key":"R33-20261007","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1001\/jama.2025.12543","article-title":"Dalbavancin for treatment of Staphylococcus aureus bacteremia: the DOTS randomized clinical trial.","volume":"334","author":"Turner","year":"2025","journal-title":"JAMA"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005430","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:01:41Z","timestamp":1791345701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/INF.0000000000005430"}},"subtitle":["Evidence and Real-life Experience With Dalbavancin and Oritavancin"],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000005430","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]}}}